In childhood,<unk>  patients can expect a 5-year event free survival and overall survival of, respectively, 70% and 80%. Amongst approximately 25% of children who relapse, survival rate sits at 30-50% and the patients show much poorer prognosis. Monitoring for MRD is critical as previously mentioned, through qPCR analysis, in order to evaluate the efficacy of treatment. Recent genomic studies have found that a selection of genetic variants in relation to clonal evolution that drive resistance have been found as the basis for<unk>  relapse. Over 20% of patients with relapsed<unk>  showed mutation in the variant cytosolic 5’-nucleotidase II (NT5C2) gene, while the TFDP3 gene has also been found to confer chemoresistance in children.
T-Cell Acute Lymphoblastic Leukemia
T-lymphoblastic leukemia/lymphoma
Adult T-cell leukemia/lymphoma
Atypical chronic myeloid leukemia
T-cell acute lymphoblastic leukemia
Aggressive NK-cell leukemia
T-cell prolymphocytic leukemia
B-cell prolymphocytic leukemia